HUTCHMED, Innovent Get Conditional Approval in China for ELUNATE With TYVYT to Treat Advanced Endometrial Cancer

MT Newswires Live

Dec 03, 2024

HUTCHMED (HCM) and Innovent Biologics said Tuesday that the new drug application for the combination of ELUNATE and TYVYT has been granted conditional approval in China for the treatment of certain patients with advanced endometrial cancer.

This follows the priority review status and breakthrough therapy designation granted by the National Medical Products Administration of China.

The approval was supported by data from the phase II study, FRUSICA-1, which showed objective response rate and disease control rate of 35.6% and 88.5% respectively.

The company further said that the combination treatment showed rapid on-set efficacy, with a median time to response of 1.6 months, and median progression-free survival and overall survival of 9.5 months and 21.3 months, respectively.

The company also plans to do a phase III confirmatory study of the combination treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2488918256"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488918256\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2488918256?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488918256","market":"fut","top_or_hot":-1,"title":"HUTCHMED, Innovent Get Conditional Approval in China for ELUNATE With TYVYT to Treat Advanced Endometrial Cancer","media":"MT Newswires Live","content":"<html><body><p> HUTCHMED (HCM) and Innovent Biologics said Tuesday that the new drug application for the combination of ELUNATE and TYVYT has been granted conditional approval in China for the treatment of certain patients with advanced endometrial cancer.</p><p>This follows the priority review status and breakthrough therapy designation granted by the National Medical Products Administration of China.</p><p>The approval was supported by data from the phase II study, FRUSICA-1, which showed objective response rate and disease control rate of 35.6% and 88.5% respectively.</p><p>The company further said that the combination treatment showed rapid on-set efficacy, with a median time to response of 1.6 months, and median progression-free survival and overall survival of 9.5 months and 21.3 months, respectively.</p><p>The company also plans to do a phase III confirmatory study of the combination treatment.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED, Innovent Get Conditional Approval in China for ELUNATE With TYVYT to Treat Advanced Endometrial Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED, Innovent Get Conditional Approval in China for ELUNATE With TYVYT to Treat Advanced Endometrial Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-03 19:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> HUTCHMED (HCM) and Innovent Biologics said Tuesday that the new drug application for the combination of ELUNATE and TYVYT has been granted conditional approval in China for the treatment of certain patients with advanced endometrial cancer.</p><p>This follows the priority review status and breakthrough therapy designation granted by the National Medical Products Administration of China.</p><p>The approval was supported by data from the phase II study, FRUSICA-1, which showed objective response rate and disease control rate of 35.6% and 88.5% respectively.</p><p>The company further said that the combination treatment showed rapid on-set efficacy, with a median time to response of 1.6 months, and median progression-free survival and overall survival of 9.5 months and 21.3 months, respectively.</p><p>The company also plans to do a phase III confirmatory study of the combination treatment.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488918256","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488918256","pubTimestamp":1733225304,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HUTCHMED  and Innovent Biologics said Tuesday that the new drug application for the combination of ELUNATE and TYVYT has been granted conditional approval in China for the treatment of certain patients with advanced endometrial cancer.This follows the priority review status and breakthrough therapy designation granted by the National Medical Products Administration of China.The approval was supported by data from the phase II study, FRUSICA-1, which showed objective response rate and disease control rate of 35.6% and 88.5% respectively.The company further said that the combination treatment showed rapid on-set efficacy, with a median time to response of 1.6 months, and median progression-free survival and overall survival of 9.5 months and 21.3 months, respectively.The company also plans to do a phase III confirmatory study of the combination treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK1191":"制药","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","BK4585":"ETF&股票定投概念","BK1587":"次新股","BK1588":"回港中概股","HCM":"和黄医药","BK4157":"电子设备和仪器","BLZ.SI":"爱文思控股","00013":"和黄医药","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","AEIS":"先进能源工业公司","BK4007":"制药","BK6522":"化石燃料股","BK4531":"中概回港概念","BK6088":"石油天然气设备与服务"},"translate_title":"和黄医药、信达生物在中国有条件批准爱优特联合达伯舒治疗晚期子宫内膜癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEIS":1,"BLZ.SI":1,"HCM":0.9,"00013":1},"content_text":"HUTCHMED (HCM) and Innovent Biologics said Tuesday that the new drug application for the combination of ELUNATE and TYVYT has been granted conditional approval in China for the treatment of certain patients with advanced endometrial cancer.This follows the priority review status and breakthrough therapy designation granted by the National Medical Products Administration of China.The approval was supported by data from the phase II study, FRUSICA-1, which showed objective response rate and disease control rate of 35.6% and 88.5% respectively.The company further said that the combination treatment showed rapid on-set efficacy, with a median time to response of 1.6 months, and median progression-free survival and overall survival of 9.5 months and 21.3 months, respectively.The company also plans to do a phase III confirmatory study of the combination treatment.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}